Publications
View our recent posters and publications:
Azetukalner in Epilepsy and Related Publications
Company Poster. “Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent Kv7 Potassium Channel Opener in Adults With Focal Epilepsy: Update From the Ongoing 7-Year Open-Label Extension of X-TOLE” 2024 Annual Meeting of the American Epilepsy Society (AES). December 6-10, 2024
Company Poster. “Is the Mental Health Burden of Epilepsy Under-Recognized in Patients Reporting Focal Onset Seizures? A Patient-Reported Outcomes Study” 2024 Annual Meeting of the American Epilepsy Society (AES). December 6-10, 2024
Company Poster. “A Targeted Literature Review of Comorbidity Burden in Focal Onset Seizures” 2024 Annual Meeting of the American Epilepsy Society (AES). December 6-10, 2024
Peer-Reviewed Journal Article in JAMA Neurology. French JA, Porter RJ, Perucca E, et al. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial. JAMA Neurol. Published online October 09, 2023.
Azetukalner in MDD
Company Poster. “Efficacy and Safety of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener in Adults With Moderate to Severe Major Depressive Disorder: Results From the Proof-of-Concept Phase 2 X-NOVA Study” Psych Congress. October 31, 2024
Xenon’s Pre-Clinical Programs
Company Poster. “Nav1.1 Potentiators Modulate Brain Rhythms Measured Through Quantitative Electrocorticography (qECoG) in a Dravet Mouse Model” 2024 Annual Meeting of the American Epilepsy Society (AES). December 6-10, 2024
Company Poster. “Selective Potentiation of Nav1.1 Channels in Dravet Mice Restores Interneuron Function and Improves Motor Function” 2024 Annual Meeting of the American Epilepsy Society (AES). December 6-10, 2024
View our Publications Archive